• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Catalent expands early-phase development skills with $139m Juniper buyout

July 3, 2018 By Sarah Faulkner

CatalentCatalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNP) and its early-stage product development services.

The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities.

“Juniper’s proven solutions and capabilities will further support Catalent’s strategic goal to be the most comprehensive partner for pharmaceutical innovators,” Jonathan Arnold, president of Catalent Oral Drug Delivery, said in prepared remarks. “Juniper’s scientific expertise in early-phase product development and supply will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster.”

Catalent’s buyout includes Juniper’s 150 employees and the chance to add to its formulation and analytical solutions, including development and clinical manufacturing resources located in Juniper’s Nottingham facility.

Catalent will also support Juniper’s Crinone progesterone gel franchise, which is sold by Merck KGaA outside of the U.S.

“This transaction, which has been approved unanimously by the Juniper Board of Directors following the recommendation of a special committee of independent directors, is the culmination of a diligent and extensive process to pursue strategic alternatives in order to maximize shareholder value,” Alicia Secor, Juniper’s president & CEO, added. “Catalent’s offer to acquire Juniper recognizes the value of Juniper’s businesses, Juniper Pharma Services and Crinone.”

The acquisition is expected to close in the first quarter of Catalent’s 2019 fiscal year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Catalent, juniperpharmaceuticals

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS